Advertisement

Current Neurology and Neuroscience Reports

, Volume 6, Issue 1, pp 37–46 | Cite as

Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene

  • Peter M. AndersenEmail author
Article

Abstract

This review highlights recent epidemiologic, clinical-genetic, and neurochemical advances in our understanding of sporadic amyotrophic lateral sclerosis (ALS) and their relationships to familial ALS caused by superoxide dismutase (SOD1) gene mutations. It is of fundamental importance to recognize that ALS is a biologically heterogeneous syndrome in which genetics, environment, and aging are inter-related. The discovery of mutations in the SOD1 gene is the greatest breakthrough in ALS research since Charcot’s description of the disorder, but the putative toxic gain of function of mutant SOD1 remains elusive despite intense research. Currently, two dominant theories for the pathogenesis of SOD1 mutations exist: specific protein cytotoxicity and protein aggregation. Mutant SOD1 interacts specifically with neurofilament-light chain mRNA and the dynein/dynactin complex, suggesting that cytoskeletal defects and axonal transport are key players. In addition, mutant SOD1 protein has increased propensity to form aggregate-prone monomers, and the degree of instability correlates inversely with length of survival; therefore, increased propensity to aggregate may be the unifying common denominator for the 119 diverse SOD1 mutations.

Keywords

Amyotrophic Lateral Sclerosis Motor Neuron Amyotrophic Lateral Sclerosis Patient SOD1 Gene G93A SOD1 Mouse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Jonghe PD, Auer-Grumbach M, Irobi J, et al.: Autosomal dominant juvenile amyotrophic lateral sclerosis and distal hereditary motor neuronopathy with pyramidal tract signs: synonyms for the same disorder? Brain 2002, 125:1320–1325.PubMedCrossRefGoogle Scholar
  2. 2.
    Forestier NL, Maisonobe T, Piquard A, et al.: Does primary lateral sclerosis exist? A study of 20 patients and a review of the literature. Brain 2001, 124:1989–1999.PubMedCrossRefGoogle Scholar
  3. 3.
    Strong M, Gordon PH: Primary lateral sclerosis, hereditary spastic paraplegia and amyotrophic lateral sclerosis: discrete entities or spectrum? Amyotroph Lateral Scler Other Motor Neuron Disord 2005, 6:8–16. Excellent review of the difficulties in making differential diagnosis between ALS and other conditions with upper motor neuron pathology.PubMedGoogle Scholar
  4. 4.
    Abrahams S, Goldstein LH, Simmons A, et al.: Word retrieval in amyotrophic lateral sclerosis: a functional magnetic resonance imaging study. Brain 2004, 127:1507–1517.PubMedCrossRefGoogle Scholar
  5. 5.
    Paviour DC, Lees AJ, Josephs KA, et al.: Frontotemporal lobar degeneration with ubiquitin-only-immunoreactive neuronal changes: broadening the clinical picture to include progressive supranuclear palsy. Brain 2004, 127:2441–2451.PubMedCrossRefGoogle Scholar
  6. 6.
    Davenport RJ, Swingler RJ, Chancellor AM, Warlow CP: Avoiding false positive diagnoses of motor neuron disease: lessons from the Scottish Motor Neuron Disease Register. J Neurol Neurosurg Psychiatry 1996, 60:147–151.PubMedGoogle Scholar
  7. 7.
    Logroscino G, Beghi E, Zoccolella S, et al.: Incidence of amyotrophic lateral sclerosis in southern Italy: a population based study. J Neurol Neurosurg Psychiatry 2005, 76:1094–1098.PubMedCrossRefGoogle Scholar
  8. 8.
    ChiÒ A, Benzi G, Dossena M, et al.: Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain 2005, 128:472–476.PubMedCrossRefGoogle Scholar
  9. 9.
    Andersen PM, Nilsson P, KerÄnen ML, et al.: Phenotypic heterogeneity in MND-patients with CuZn-superoxide dismutase mutations in Scandinavia. Brain 1997, 10:1723–1737.CrossRefGoogle Scholar
  10. 10.
    Andersen PM, Sims KB, Xin WW, et al.: Sixteen novel mutations in the gene encoding CuZn-superoxide dismutase in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2003, 2:62–73. A large screening study of 2045 ALS patients for SOD1 mutations. A number of patients presented with very atypical features resulting in difficulties in setting the diagnosis. Several patients with SOD1 mutations had been diagnosed as SALS.CrossRefGoogle Scholar
  11. 11.
    Jones CT, Swingler RJ, Simpson SA, Brock DJ: Superoxide dismutase mutations in an unselected cohort of Scottish amyotrophic lateral sclerosis patients. J Med Genet 1995, 32:290–292.PubMedGoogle Scholar
  12. 12.
    Aggarwal A, Nicholson G: Age dependent penetrance of three different superoxide dismutase 1 (SOD1) mutations. Int J Neurosci 2005, 115:1119–1130.PubMedCrossRefGoogle Scholar
  13. 13.
    McDermott CJ, Roberts D, Tomkins J, et al.: Spastin and paraplegin gene analysis in selected cases of MND. Amyotroph Lateral Scler Other Motor Neuron Disord 2003, 4:96–99.PubMedCrossRefGoogle Scholar
  14. 14.
    Rosen DR, Siddique T, Patterson D, et al.: Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59–62.PubMedCrossRefGoogle Scholar
  15. 15.
    Liu J, Concepcion L, Jonsson PA, et al.: Toxicity from copper chaperone and dismutase activity-independent accumulation of familial ALS-causing SOD1 mutants with spinal cord mitochondria. Neuron 2004, 43:5–17.PubMedCrossRefGoogle Scholar
  16. 16.
    Pasinelli P, Belford ME, Lennon N, et al.: ALS-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron 2004, 43:19–30.PubMedCrossRefGoogle Scholar
  17. 17.
    Jonsson A, Ernhill K, Andersen PM, et al.: Motor neuron disease in ALS patient and transgenic mice carrying Gly127insTGGG mutant Human CuZn-Superoxide Dismutase. Brain 2004, 127:73–88.PubMedCrossRefGoogle Scholar
  18. 18.
    Restagno G, Gomez A, Lombardo F, et al.: The IVS1 +319 t>a of SOD1 gene is not an ALS causing mutation. Amyotroph Lateral Scler Other Motor Neuron Disord 2005, 6:45–49.PubMedCrossRefGoogle Scholar
  19. 19.
    Fukae J, Kubo SI, Hattori N, et al.: Hoarseness due to bilateral vocal cord paralysis as an initial manifestation of familial ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2005, 6:122–124.PubMedCrossRefGoogle Scholar
  20. 20.
    Boukaftane Y, Khoris J, Moulard B, et al.: Identification of six novel SOD1 gene mutations in familial amyotrophic lateral sclerosis. Can J Neurol Sci 1998, 25:192–196.PubMedGoogle Scholar
  21. 21.
    Battistini S, Giannini F, Greco G, et al.: SOD1 mutations in amyotrophic lateral sclerosis. Results from a multicenter Italian study. J Neurol 2005, 252:782–788.PubMedCrossRefGoogle Scholar
  22. 22.
    Jackson M, Al-Chalabi A, Enayat ZE, et al.: Copper/zinc superoxide dismutase 1 and sporadic amyotrophic lateral sclerosis: analysis of 155 cases and identification of a novel insertion mutation. Ann Neurol 1997, 42:803–807.PubMedCrossRefGoogle Scholar
  23. 23.
    Garcia-Redondo A, Bustos F, Juan Y, et al.: Molecular analysis of the superoxide dismutase 1 gene in Spanish patients with sporadic or familial amyotrophic lateral sclerosis. Muscle Nerve 2002, 26:274–278.PubMedCrossRefGoogle Scholar
  24. 24.
    Gellera C: Genetics of ALS in Italian families. Amyotroph Lateral Scler Other Motor Neuron Disord 2001, 2(Suppl 1):S43-S46.PubMedCrossRefGoogle Scholar
  25. 25.
    Robberecht W, Aguirre T, Bosch LV, et al.: D90A heterozygosity in the SOD1 gene is associated with familial and apprently sporadic ALS. Neurology 1996, 47:1336–1339.PubMedGoogle Scholar
  26. 26.
    Rezania K, Yan J, Dellefave L, et al.: A rare Cu/Zn superoxide dismutase mutation causing familial ALS with variable age of onset, incomplete penetrance and a sensory neuropathy. Amyotroph Lateral Scler Other Motor Neuron Disord 2003, 4:162–166.PubMedGoogle Scholar
  27. 27.
    Garré C, Ferrera L, Caponetto C, et al.: An Italian dominant FALS Leu144Phe SOD1 mutation: genotypephenotype correlation. Amyotroph Lateral Scler Other Motor Neuron Disord 2003, 4:167–170.PubMedCrossRefGoogle Scholar
  28. 28.
    Andersen PM, Forsgren L, Binzer M, et al.: Autosomal recessive adult-onset ALS associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain 1996, 119:1153–1172.PubMedCrossRefGoogle Scholar
  29. 29.
    Alexander MD, Traynor BJ, Miller N, et al.: "True" sporadic ALS associated with novel SOD-1 mutation. Ann Neurol 2002, 52:680–683.PubMedCrossRefGoogle Scholar
  30. 30.
    Weber M, Eisen A, Stewart HG, Andersen PM: Preserved slow conducting corticomotoneuronal projections in ALS patients with autosomal recessive D90A CuZn-SOD mutation. Brain 2000, 123:1505–1515.PubMedCrossRefGoogle Scholar
  31. 31.
    Cudkowicz ME, McKenna-Yasek D, Sapp PE, et al.: Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol 1997, 41:210–221.PubMedCrossRefGoogle Scholar
  32. 32.
    Niemann S, Joos H, Meyer T, et al.: Familial ALS in Germany: origin of the R115G SOD1 mutation by a founder effect. J Neurol Neurosurg Psychiatry 2004, 75:1186–1188.PubMedCrossRefGoogle Scholar
  33. 33.
    Turner MR, Hammers A, Al-Chalabi A, et al.: Distinct cerebral lesions in sporadic and ‘D90A’ SOD1 ALS: Studies with [11C]-flumazenil PET. Brain 2005, 128:1323–1329. Flumazenil is a GABA-ligand. Eleven D90A-homozygous patients as well as two D90A-homozygous unaffected relatives were studied. Extensive changes were found in non-motor areas, in particular in the left frontal lobe region. The changes were radically different from the ones observed in 24 patients without SOD1 gene mutations.PubMedCrossRefGoogle Scholar
  34. 34.
    Hayward C, Brock DJ, Minns RA, Swingler RJ: Homozygosity for Asn86Ser mutation in the CuZn-superoxide dismutase gene produces a severe clinical phenotype in a juvenile onset case of familial amyotrophic lateral sclerosis. J Med Genet 1998, 35:174.PubMedCrossRefGoogle Scholar
  35. 35.
    Kato M, Aoki M, Ohta M, et al.: Marked reduction of the Cu/Zn superoxide dismutase polypeptide in a case of familial ALS with the homozygous mutation. Neurosci Lett 2001, 312:165–168.PubMedCrossRefGoogle Scholar
  36. 36.
    Agar J, Durham H: Relevance of oxidative injury in the pathogenesis of motor neuron disease. Amyotroph Lateral Scler Other Motor Neuron Disord 2003, 4:232–242.PubMedCrossRefGoogle Scholar
  37. 37.
    Clement AM, Nguyen MD, Roberts EA, et al.: Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003, 302:113–117. Chimeric mice were generated with various proportions of neural and non-neuronal cells with SOD1 mutations. The result is intriguing: it appears that "LMN may be innocent by-standers that are killed by their bad neighbors," but this theory needs confirmation.PubMedCrossRefGoogle Scholar
  38. 38.
    Tikka TM, Vartiainen NE, Goldsteins G, et al.: Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neuron disease. Brain 2002, 125:722–731. The authors found that CSF from ALS patients with and without SOD1 mutations had a similar neurotoxic effect to motor neurons in culture, and the effect was blocked by minocycline.PubMedCrossRefGoogle Scholar
  39. 39.
    Drory VE, Gross D: No effect of creatine on respiratory distress in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002, 3:43–46.PubMedCrossRefGoogle Scholar
  40. 40.
    Aggarwal A, Nicholson G: Normal complement of motor units in asymptomatic familial (SOD1 mutation) amyotrophic lateral sclerosis carriers. J Neurol Neurosurg Psychiatry 2001, 71:478–481.PubMedCrossRefGoogle Scholar
  41. 41.
    Krasnianski A, Deschauer M, Neudecker S, et al.: Mitochondrial changes in skeletal muscle in amyotrophic lateral sclerosis and other neurogenic atrophies. Brain 2005, 128:1870–1876.PubMedCrossRefGoogle Scholar
  42. 42.
    Lindberg MJ, Byström R, BokanÄs N, et al.: Systematically perturbed folding patterns of ALS-associated SOD1 mutants. Proc Natl Acad Sci U S A 2005, 102:9754–9759. The researchers expressed in Escherichia coli the 15 ALSOD mutations from which the best clinical data are available. The purified mutant proteins’ propensity to denaturate and form monomers of stability was analyzed and found to correlate with disease survival time. This is the first time a correlation has been found between protein instability and survival time.PubMedCrossRefGoogle Scholar
  43. 43.
    Rakhit R, Crow JP, Lepock JR, et al.: Monomeric Cu,Zn-superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial ALS. J Biol Chem 2004, 279:15499–15504.PubMedCrossRefGoogle Scholar
  44. 44.
    Vlug AS, Jaarsma D: Long term proteasome inhibition does not preferentially afflict motor neurons in organotypical spinal cord cultures. Amyotroph Lateral Scler Other Motor Neuron Disord 2004, 5:16–21.PubMedCrossRefGoogle Scholar
  45. 45.
    Menzies FM, Cookson MR, Taylor RW, et al.: Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain 2002, 125:1522–1533.PubMedCrossRefGoogle Scholar
  46. 46.
    Ge WW, Wen W, Strong W, et al.: Mutant copper-zinc superoxide dismutase binds to and destabilizes human low molecular weight neurofilament mRNA. J Biol Chem 2005, 280:118–124. Private mutations in the neurofilament heavy chain gene had been found earlier in SALS and FALS, but this is the first study to give the neurofilament light chain gene a direct role in ALS pathogenesis. The proposed gain of noxius function is very interesting but needs confirmation on a much larger group of SOD1 mutants, including some of the truncated ones.PubMedGoogle Scholar
  47. 47.
    Kieran D, Hafezparast M, Bohnert S, et al.: A mutation in dynein rescues axonal transport defects and extends the life span of ALS mice. J Cell Biol 2005, 169:561–567. The apriori hypothesis was that the crossbreeding of mice with dynein mutation with G93A SOD1 mice should result in a very aggressive form of murine MND. The opposite result was observed and has been reproduced. This excellent study suggests that active retrograde axonal transport plays a key role in ALSOD pathogenesis.PubMedCrossRefGoogle Scholar
  48. 48.
    Ligon LA, LaMonte BL, Wallace KE, et al.: Mutant superoxide dismutase disrupts cytoplasmic dynein in motor neurons. Neuroreport 2005, 16:533–536.PubMedCrossRefGoogle Scholar
  49. 49.
    Ravikumar B, Acevedo-Arozena A, Imarisio S, et al.: Dynein mutations impair autophagic clerance of aggregate-prone proteins. Nat Genet 2005, 37:771–776.PubMedCrossRefGoogle Scholar
  50. 50.
    Fischer EM, Ahmad-Annuar A, Shah P, et al.: No association with genotypes in exons 8, 13 and 14 of the human cytoplasmic dynein heavy chain gene (DNCHC1) and familial ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2003, 4:150–157.CrossRefGoogle Scholar
  51. 51.
    Puls I, Oh SJ, Sumner CJ, et al.: Distal spinal and bulbar muscular atrophy caused by dynactin mutation. Ann Neurol 2005, 57:687–694. SBMA is an ALS-like disorder without UMN signs. The missense mutation was found to be co-segregated with disease and must be considered to be disease causative.PubMedCrossRefGoogle Scholar
  52. 52.
    Münch C, Sedlmeier R, Meyer T, et al.: Point mutation of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology 2004, 63:724–726. The patients studied were two siblings with ALS and two SALS cases. The mutations found have not been proven to be causative, but the balance of evidence points in that direction. What is needed is a large, multigeneration ALS-pedigree where a dynactin mutation co-segregates with the disease+.PubMedGoogle Scholar
  53. 53.
    Münch C, Rosenbohm A, Sperfeld AD, et al.: Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD. Ann Neurol 2005, 58:777–780.PubMedCrossRefGoogle Scholar
  54. 54.
    Shaw CE, Enayat ZE, Chioza BA, et al.: Mutations in all five exons of SOD-1 may cause ALS. Ann Neurol 1998, 43:390–394.PubMedCrossRefGoogle Scholar
  55. 55.
    Orrell RW, Habgood JJ, Gardiner I, et al.: Clinical and functional investigation of 10 missense mutations and a novel frameshift insertion mutation of the gene for copper-zinc superoxide dismutase in UK families with amyotrophic lateral sclerosis. Neurology 1997, 48:746–751.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Department of NeurologyUmeå University HospitalUmeåSweden

Personalised recommendations